|
Previous article 
Next article |
|
|
EDITORIAL
Year : 2012 | Volume
: 6
| Issue : 2 | Page : 104-106
Dexmedetomidine: A look at a promising new avenue of use
Thomas M Halaszynski
Associate Professor of Anesthesiology, Director, Orthopedics and Regional Anesthesiology, Department of Anesthesiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06525, USA
Correspondence Address:
Thomas M Halaszynski
Associate Professor of Anesthesiology, Director, Orthopedics and Regional Anesthesiology, Department of Anesthesiology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06525
USA
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1658-354X.97019
| Date of Web Publication | 8-Jun-2012 |
|
|
How to cite this article:
Halaszynski TM. Dexmedetomidine: A look at a promising new avenue of use. Saudi J Anaesth 2012;6:104-6 |
Alpha (α)-2-adrenergic receptor (α2-AR) agonists have been utilized in a host of clinical scenarios secondary to the hemodynamic-stabilizing properties, sedative, analgesic, and sympatholytic pharmacologic effects of the agent.[1] In addition, α2-AR medications such as dexmedetomidine have demonstrated a dose-dependent increase in the duration of thermal antinociception and analgesia in some animal studies.[2],[3] Therefore, many of these advantageous effects of adding dexmedetomidine to local anesthetics during regional anesthesia and peripheral nerve blockade procedures may also prove efficacious for the surgical patient. This editorial examined the study performed by Mahmoud et al., entitled "Ultrasound-guided single-injection infraclavicular brachial plexus block using bupivacaine alone or combined with dexmedetomidine for pain control in upper limb surgery [4]" (reference the article here). Assessment of this investigation looked to provide an overview and critique of the article's current clinical status along with any potential new therapeutic avenues it may suggest. Can adding dexmedetomidine to local anesthetics provide for perioperative anesthetic-sparing and reduced postoperative rescue opioid requirements?
Dexmedetomidine is a selective α2-AR agonist with evidence of an increased ratio of α2-to-α1 activity of 1620:1, as compared to 220:1 when contrasted against clonidine. The mechanism by which α2-AR agonists produce analgesia and sedation is not fully understood, but is likely to be multi-factorial. Dexmedetomidine possesses analgesic properties and many other advantageous influences, but also lacks respiratory depression [5],[6] that may make it a useful and safe adjunct in many diverse clinical applications. Both hypnotic and supraspinal analgesic effects of dexmedetomidine are mediated by noradrenergic neurons (via hyperpolarization). This mechanism of action: 1) causes inhibition of norepinephrine release and its associated activity in the descending medullo-spinal noradrenergic pathway (secondary to activation of central α2-ARs) and 2) suppresses neuronal firing in the locus coeruleus.[2],[7] Suppression of these inhibitory controls causes release of mediators and neurotransmitters that in turn decrease the secretion of histamine and produce hypnosis (very similar to normal sleep), all without evidence of depression of ventilation. [8] In addition, suppression of activity along the descending noradrenergic pathway (responsible for modulation of nociceptive neurotransmission) terminates propagation of pain signals, resulting in analgesia or decreased awareness of noxious stimuli.
In neurons of the superficial dorsal horn of the spinal cord, dexmedetomidine suppresses and reduces pain transmission/conduction 1) by inhibiting the release of glutamate and substance P (nociceptive transmitters) from primary afferent terminals and 2) with G-protein-mediated activation of potassium channels causing hyperpolarization of inter-spinal neurons. The stress response to surgery can be attenuated by sympatholytic effects caused by postsynaptic activation of central α2-ARs, leading to reductions in blood pressure and slowing of the heart rate.[9],[10]
Dexmedetomidine administered intravenously has been used for sedation and anxiolysis in the intensive care unit, as the sole agent during procedural sedation, and as a host of additional perioperative uses: premedication, to reduce emergence delirium and postoperative pain, to attenuate the stress responses associated with surgery and anesthesia (intubation, extubation, emergence), and for numerous other indications. When used as an adjunct to general anesthesia, dexmedetomidine can reduce both the minimum alveolar concentration (MAC) requirement of inhalation agents and provide opiate-sparing properties up to 90%. [11] This property enables an advantage in situations where high anesthetic concentration is undesirable, such as with certain neurosurgical procedures, minimally invasive endoscopic procedures, outpatient surgery, etc.
However, an emerging application is the role of dexmedetomidine in facilitating acute and chronic pain management. The α2-AR agonist, selectivity of dexmedetomidine, enhances the therapeutic window during treatment of pain, along with opiate-sparing effects important in the management of acute postoperative pain and chronic pain states (neuropathic pain, sympathetically maintained pain such as complex regional pain syndrome (CRPS) and chronic headaches). Dexmedetomidine is also transitioning as an adjuvant analgesic for intravenous and intrathecal infusion, during placement of peripheral nerve blockade, in the treatment of cancer pain, and in synergy with local anesthetics resulting in prolonged epidural anesthesia and analgesia.
Animal studies have not shown any evidence of neurotoxicity when administering dexmedetomidine (even at high concentrations) directly to sciatic nerves in a rat model investigation. [12] Brummett and colleagues [13],[14] showed that adding dexmedetomidine to ropivacaine resulted in a dose-dependent increase in the duration of both sensory and motor blockade in a similar rat model study. There have been a few clinical studies evaluating the effect of mixing dexmedetomidine with local anesthetics during placement of peripheral nerve blockade. Peripheral analgesic effects of dexmedetomidine have enabled an overall improved blockade quality when added to local anesthetics in a peripheral nerve block model and are thought to be mediated by α2-AR binding.[15] In a randomized double-blind trial performed by Esmaoglu et al., [16] dexmedetomidine added to levobupivacaine for axillary brachial plexus blockade shortened the block onset time, prolonged the duration of motor and sensory effects, and extended postoperative analgesia. In addition, dexmedetomidine mixed with lidocaine has been reported to decrease tourniquet pain, improve block quality, and prolong postoperative analgesia during intravenous regional anesthesia. [17]
Results of some of the recent research identified above have indicated that α2-AR agonists may dose dependently enhance local anesthetic effectiveness and prolong its duration. However, additional possible mechanisms associated with dexmedetomidine that need further investigation to examine its actions in the periphery could be: 1) vasoconstriction around the site of injection (resulting in a delay of the absorption of local anesthetic); 2) prolonged local anesthetic effect possibly by α2-AR agonists interfering with absorption of local anesthetics injected by vasoconstriction since α2-ARs are involved in the control of arterial blood pressure; and 3) nonselective α2-AR agonists create a biphasic arterial blood pressure response (short hypertensive phase and subsequent hypotension). In addition, other investigators have supported another mechanism for the action of α2-AR agonists rather than vasoconstriction, such as a direct effect on peripheral nerve activity.[18] Clonidine has been shown to directly interrupt peripheral nerve action; therefore, the effect of α2-AR agonists may be induced by a direct action toward peripheral blood vessels or peripheral nerves or some component of each. [19]
Studies have demonstrated that dexmedetomidine and clonidine enhance local anesthetic action (by peripheral α2-AR). Dexmedetomidine has some advantageous pharmacological characteristics compared with similar sedative medications: 1) hemodynamic stability achieved with dexmedetomidine compared to clonidine is related to the fact that it is more selective for α2-AR and 2) both baroceptor reflex and heart rate response to a pressor are well preserved with dexmedetomidine. These important findings may suggest that dexmedetomidine has enhanced safety as an adjunct to local anesthetics in patients with cardiovascular disease, compared with other vasoconstrictors (e.g. epinephrine). Dexmedetomidine can result in adverse side effects like hypotension and bradycardia with increased dosage in addition to its effects of sedation and anxiolysis, and further studies are needed to better understand these side effects and the safe optimal dose of dexmedetomidine.
Dexmedetomidine is a potent α2-AR agonist and has widespread actions on the mammalian brain (sedation), in the neuraxial space (sympatholytic properties), and in the periphery during regional anesthesia with peripheral nerve blockade (anesthetic-sparing and postoperative analgesia). A large body of work and supporting fund of knowledge supports its favorable profile in improving the outcome and long-term function without evidence of destructive neurologic impact. Sources of such benefits are seen in the neuroprotective properties that are evident in experimental animal models as well as in the clinical setting. However, it will be necessary to explore the pharmacological mechanisms for the actions of α2-AR agonist in more detail. Dexmedetomidine may continue to be a valuable adjuvant when regional anesthesia is incorporated, but further research should focus on establishing the safe dose response requirements and optimal risk/benefit ratio when used with regional anesthesia techniques.
| Acknowledgment | |  |
Commercial or institutional resources did not sponsor this article and the author received no financial support. The author has no conflict of interest with regard to this article.
| References | | |
| 1. | Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anesthesia 1999;54:146-65. 
|
| 2. | Brummett CM, Padda AK, Amodeo FS, Welch KB, Lydic R. Perineural dexmedetomidine added to ropivacaine causes a dose-dependent increase in the duration of thermal antinociception in sciatic nerve block in rat. Anesthesiology 2009;111:1111-9.
[PUBMED] [FULLTEXT] |
| 3. | Brummett CM, Amodeo FS, Janda AM, Padda AK, Lydic R. Perineural dexmedetomidine provides an increased duration of analgesia to a thermal stimulus when compared with a systemic control in a rat sciatic nerve block. Reg Anesth Pain Med 2010;35:427-31.
[PUBMED] [FULLTEXT] |
| 4. | Mahmoud KM, Ammar AS. Ultrasound-guided single injection infraclavicular brachial plexus block using bupivacaine alone or combined with dexmedetomidine for pain control in upper limb surgery: A prospective randomized controlled trial. Saudi J Anaesth 2012;6:109-14.
 |
| 5. | Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: A review of clinical applications. Curr Opin Anaesthesiol 2008;21:457-61.
[PUBMED] [FULLTEXT] |
| 6. | Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg 2000;90:699-705.
[PUBMED] [FULLTEXT] |
| 7. | Ishii H, Kohno T, Yamakura T, Ikoma M, Baba H. Action of dexmedetomidine on the substantia gelatinosa neurons of the rat spinal cord. Eur J Neurosci 2008;27:3182-90.
[PUBMED] [FULLTEXT] |
| 8. | Nelson LE, You T, Maze M, Franks NP. Evidence that the mechanism of hypnotic action in dexmedetomidine and muscimol-induced anesthesia converges on the endogenous sleep pathway. Anesthesiology 2001;95:A1368.
|
| 9. | Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY. Monitored anesthesia care with dexmedetomidine: A prospective, randomized, double-blind, multicenter trial. Anesth Analg 2010;110:47-56.
|
| 10. | Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg 2002;95:461-6.
[PUBMED] [FULLTEXT] |
| 11. | Aho M, Erkola O, Kallio A, Scheinin H, Korttila K. Dexmedetomidine infusion for maintenance of anesthesia in patients undergoing abdominal hysterectomy. Anesth Analg 1992;75:940-6.
[PUBMED] [FULLTEXT] |
| 12. | Brummett CM, Norat MA, Palmisano JM, Lydic R. Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat. Anesthesiology 2008;109:502-11.
[PUBMED] [FULLTEXT] |
| 13. | Brummett CM, Amodeo FS, Janda AM, Padda AK, Lydic R. Perineural dexmedetomidine provides an increased duration of analgesia to a thermal stimulus when compared with a systemic control in a rat sciatic nerve block. Reg Anesth Pain Med 2010;35:427-31.
[PUBMED] [FULLTEXT] |
| 14. | Brummett CM, Padda A, Amadeo FS, Welch KB, Lydic R. Perineural dexmedetomidine added to ropivacaine causes a dose-dependent increase in the duration of thermal antinociception in sciatic nerve block in rat. Anesthesiology 2009;111:1111-9.
|
| 15. | Yoshitomi T, Kohjitani A, Maeda S, Higuchi H, Shimada M, Miyawaki T. Dexmedetomidine enhances the local anesthetic action of lidocaine via an alpha-2A adrenoceptor. Anesth Analg 2008;107:96-101.
[PUBMED] [FULLTEXT] |
| 16. | Esmaoglu A, Yegenoglu F, Akin A, Turk CY. Dexmedetomidine added to levobupivacaine prolongs axillary brachial plexus block. Anesth Analg 2010;111:1548-51.
|
| 17. | Ramadhyani U, Park JL, Carollo DS, Waterman RS, Nossaman BD. Dexmedetomidine: Clinical application as an adjunct for intravenous regional anesthesia. Anesthesiol Clin 2010;28:709-22.
[PUBMED] [FULLTEXT] |
| 18. | Kanazi GE, Aouad MT, Jabbour-Khoury SI, Al Jazzar MD, Alameddine MM, Al-Yaman R, et al. Effect of low-dose dexmedetomidine or clonidine on the characteristics spinal block. Acta Anaesthesiol Scand 2006;50:222-7.
[PUBMED] [FULLTEXT] |
| 19. | Gaumann DM, Brunet PC, Jirounek P. Clonidine enhances the effects of lidocaine on C-fiber action potential. Anesth Analg 1992;74:719-25.
[PUBMED] [FULLTEXT] |
| This article has been cited by | | 1 |
Efficacy and safety of wound infiltration modalities for postoperative pain management after cesarean section: a systematic review and network meta-analysis protocol |
|
| Semagn Mekonnen Abate, Getachew Mergia, Solomon Nega, Bivash Basu, Moges Tadesse | | Systematic Reviews. 2022; 11(1) | | [Pubmed] | [DOI] | | | 2 |
ADDITION OF DEXMEDETOMIDINETO LIGNOCAINE FOR INTRAVENOUS REGIONAL ANESTHESIA IN UPPER EXTREMITY ORTHOPAEDIC SURGERIES |
|
| SANTOSH KUMAR SINGH, GAURAV MITTAL, ASHOK ROUT, DEWENDRAJ GAJBHIYE, PRADEEP KEDAR | | Asian Journal of Pharmaceutical and Clinical Research. 2022; : 110 | | [Pubmed] | [DOI] | | | 3 |
A randomized comparison between interscalene block and dexmedetomidine for arthroscopic shoulder surgery |
|
| Sushma Thimmaiah Kanakalakshmi, Manjunath Prabhu, Nita Varghese, Vivek Pandey | | Colombian Journal of Anesthesiology. 2022; | | [Pubmed] | [DOI] | | | 4 |
Effects of dexmedetomidine on the onset and duration of action in non-depolarizing neuromuscular relaxant rocuronium |
|
| Jiaqi Shan, Xiaofeng Wang, Xiaoli Zhang, Junfeng Zhang | | European Journal of Inflammation. 2021; 19: 2058739221 | | [Pubmed] | [DOI] | | | 5 |
Perioperative effect of dexmedetomidine on quality of analgesia and hemodynamic parameters in vaginal hysterectomy: A tertiary centre experience |
|
| Nishit Sud, Sunil Sinha | | Indian Journal of Clinical Anaesthesia. 2021; 8(4): 561 | | [Pubmed] | [DOI] | | | 6 |
Comparison of preemptive analgesia with bupivacaine versus bupivacaine-dexmedetomidine in femoral block for fracture femur |
|
| Aparna Bagle, ShreyankP Solanki, Tanya Gulia, Shivangi Gaur, Chaitanya Gaidhani, Spoorti Pujari | | International Journal of Health & Allied Sciences. 2020; 9(3): 233 | | [Pubmed] | [DOI] | | | 7 |
EFFECT OF DEXMEDETOMIDINE AS AN ADJUVANT WITH LEVOBUPIVACAINE IN AXILLARY BRACHIAL PLEXUS BLOCK |
|
| Rajkumar P, Murugesan K | | Journal of Evolution of Medical and Dental Sciences. 2018; 7(16): 1974 | | [Pubmed] | [DOI] | | | 8 |
DEXMEDETOMIDINE AS AN ADJUNCT TO 0.5% LIGNOCAINE FOR INTRAVENOUS REGIONAL ANAESTHESIA FOR UPPER LIMB SURGERIES |
|
| Shilpashri A M, Kavya K G, Priodarshi Roychoudhury | | Journal of Evidence Based Medicine and Healthcare. 2015; 2(34): 5171 | | [Pubmed] | [DOI] | | | 9 |
Perioperative Analgesia: Ever Changing Technology and Pharmacology |
|
| Alan David Kaye,Syed Irfan Q. Ali,Richard Urman | | Best Practice & Research Clinical Anaesthesiology. 2014; | | [Pubmed] | [DOI] | | | 10 |
Sedative effect of dexmedetomidine combined with midazolam during brachial plexus blockade |
|
| Shi, Y. and Yu, C. and Zhao, B. and Peng, X. and Zhang, C. and Wu, M. | | Medical Journal of Wuhan University. 2013; 34(1): 118-121 | | [Pubmed] | |
|
|
|
| |
|
|
|
| Article Access Statistics | | | Viewed | 5902 | | | Printed | 135 | | | Emailed | 3 | | | PDF Downloaded | 563 | | | Comments | [Add] | | | Cited by others | 10 | | |
|
|
Search Pubmed for